Pharmacia & Upjohn Company

Pfizer Corporation

The Upjohn Co.

Vincent E Groppi, Jr

David W Piotrowski

Eric Jon Jacobsen

Jason K Myers

Daniel Patrick Walker

Brad A Acker

Donn G Wishka

Bruce Nelsen Rogers

Jeffrey W Corbett

Alice L Bodnar

Mark L Wolfe

Steven Charles Reitz

Anthony W Yem

Martin R Deibel, Jr

Mitchell B Berkenpas

Robert C Gadwood

Mark R Rauckhorst

The invention relates ton novel methods for measuring ion channel transmission and methods and compositions useful in the indentification of ligand gated channel agonists and modulators.

Double mutant alpha-7 nicotinic acetylcholine receptors

The invention provides compounds of Formula I: wherein Azabicyclo is where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which &#x3b1;7 is known to be involved.

[object Object]

The invention provides compounds of Formula I: where in W is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which &#x3b1;7 is known to be involved.

Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

The invention provides compounds of Formula I:wherein Azabicyclo isW is a six-membered heterocyclic ring system having 1&#x2013;2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1&#x2013;2 substitutents independently selected from R. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which &#x3b1;7 is known to be involved.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I:wherein Azabicyclo is any of:These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &#x3b1;7 is known to be involved.

Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease

The invention provides compounds of Formula I:Azabicyclo-N(R)&#x2014;C(&#x2550;X)&#x2014;W&#x2003;&#x2003;Formula IThese compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &#x3b1;7 is known to be involved.

Azabicyclic-substituted-heteroaryl compounds for the treatment of disease

The invention provides compounds of Formula I:

Substituted azabicyclic moieties for the treatment of disease

The invention provides compounds of Formula I:These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which &#x3b1;7 is known to be involved.

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I:These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which &#x3b1;7 is known to be involved.

Substituted-aryl compounds for treatment of disease

The invention provides compounds of Formula I:wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &#x3b1;7 is known to be involved.

N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease

Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease

The invention relates to a novel methods for measuring cellular ion channel transmission and methods and compositions useful in the identification of ligand gated ion channel agonists and modulators.

Growing community of inventors

Kalamazoo, MI, United States of America

Vincent E Groppi, Jr